Cyabra Prices AI Reputation, Not the 150.6M-Share Resale Stack

Summary: Cyabra (CYAB) is a conditional U.S. short setup, not an immediate trade. Its July 31 Form S-1 registers up to 150,621,827 shares against 15,765,372 common shares outstanding as of July 29, a 955% registered-to-filed-denominator ratio.[1] The stack includes July PIPE shares, immediately exercisable pre-funded warrants, approval-dependent warrants, and preferred exchange and conversion claims. Those are potential supply, not current float. The short becomes interesting only if registration and approval turn into actual issuance or resale while cash burn remains visible. entry.price is therefore null and execution remains fail-closed.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Conditional short `CYAB` common	U.S. post-de-SPAC / preferred conversion / resale registration	150.6M registered shares against 15.8M filed common shares, a completed $6M PIPE, approval-dependent conversion, and a July 31 lower-quorum bylaw create a monitorable supply path.	High: July 9 and July 31 SEC filings	Days to six weeks	A move from $0.296 toward $0.25 is a 15.5% decline; approval or non-dilutive funding can instead push the stock toward the $0.435 to $0.50 financing levels.	High potential supply, but not immediate float	The stock already trades below the $0.435 PIPE price and the approval path can create a squeeze.
2	Conditional short `MBRX` common	U.S. biotech / fresh best-efforts financing	The August 3 Form 424B5 offers up to 49.5M common-equivalent shares against a much smaller filed denominator, but the stock has already collapsed and the MIRACLE clinical data is a live countercase.	Very high: August 3 SEC filing	Days to weeks	A fresh offering or clinical update can move the stock more than 5% in either direction.	High capacity, weak timing after an extreme washout	RSI was about 8.9 and the quote was already far below the $0.75 offering price.
3	Conditional short `ELPW` common	U.S.-listed foreign issuer / reset warrants	The July offering and July 21 reset disclosure show repeated common, pre-funded, and warrant issuance, but the stock had already fallen roughly 47% from the July 31 close by the latest snapshot.	High: July 21 6-K and July 22 F-1	Days to weeks	Further financing or warrant activity can create another gap.	Large financing stack, but exhausted price action	RSI was about 20.2, the stock was near its six-month low, and borrow and execution data were unverified.

Selected opportunity: Conditional short CYAB common.

Why this one now: CYAB has the best combination of fresh primary evidence, a large filing-defined denominator mismatch, a dated approval and registration path, and enough remaining price distance for a two-sided move. MBRX has fresher financing evidence but has already suffered a violent repricing and carries a material clinical squeeze risk. ELPW has a larger apparent supply problem but is even more washed out. CYAB appeared only as a rejected candidate in the July 14 GIPR screen, never as the selected article. The new S-1, preferred conversion terms, and quorum amendment make this a materially different thesis.

What should surprise a sophisticated reader: The 955% figure is not a forecast that 150.6M shares will hit the tape. The important new fact is that the gates around part of that stack are becoming easier to monitor: the company filed the resale registration, the board reduced the stockholder-meeting quorum to 33 1/3%, and the July PIPE already created immediately exercisable pre-funded-warrant claims. The market-cap field can also mislead. A finance snapshot displayed roughly $1.04M, while 15,765,372 filed shares at the $0.296 reference price imply approximately $4.67M. The filing denominator is the safer base.

Why This Is the Best Opportunity Right Now

This is an inference, not a directly observed market belief: the tape may still be valuing CYAB primarily as an AI reputation-monitoring operating story while underweighting the mechanics of a new, registered claim stack. The stock has already fallen about 92% from its March 27 first daily close, so the dilution thesis is not a free short. The edge is narrower and more specific: the next approval, effectiveness, resale, or cash-and-share-count filing can force the market to reconcile a small current common denominator with a much larger set of registered claims.

The strongest objection is that the market may already know all of this. CYAB trades below the July PIPE price, the pre-funded warrants may remain unexercised, the Series A and Series B warrants require stockholder approval, and holders control the pace of resale. That objection is strong enough to keep this at a conditional Short Note rather than an active trade.

Why This Can Jump Or Dump More Than 5% Soon

At the market snapshot used here, CYAB was $0.296 at 14:39:07 UTC on August 3, 2026, or 22:39:07 Singapore time, with an intraday range of $0.252 to $0.300 and 7,222,918 shares reported. The prior regular-session close was $0.310, with 255,000 shares reported on July 31.[5] Intraday volume is not settled and is not proof of short selling, but the flow change is large enough to make the supply question live.

The downside path does not need a full conversion. A verified resale, pre-funded exercise, or approval-related supply signal could move $0.296 toward the recent $0.25 area, a decline of about 15.5%. The upside path is equally clear. A failed approval, credible non-dilutive financing, strong customer evidence, or a holder decision to delay resale could push the stock toward the $0.435 PIPE price and the $0.45 to $0.50 warrant levels. Those are 47% to 69% above the reference price. Technical weakness is timing evidence only. The thesis still stands without the RSI calculation.

What Should Surprise the Reader

The surprising fact is not “microcap dilution.” It is the sequence of gates.

The July 10 PIPE closed for approximately $6M gross. It included 1,175,090 common shares and pre-funded warrants for up to 12,643,680 shares. The pre-funded warrants are exercisable immediately, while the Series A and Series B warrants for 13,818,770 shares each begin only after stockholder approval.[2]
The same July agreements cover the exchange of $10.66M of Series C preferred value and the conversion of 35,648,276 Series A and Series B preferred shares. Those transactions are subject to stockholder approval and do not translate one-for-one into a current common-share count.[2]
The July 31 S-1 registers 150,621,827 shares for resale and states that the company receives no proceeds from selling-stockholder resales. It may receive up to approximately $36.4M if certain warrants are exercised for cash, but that cash is not guaranteed.[1]
The July 31 bylaw amendment reduced the stockholder-meeting quorum to 33 1/3%.[3] That may make approval easier, but it is not approval and it is not issuance.

The Setup

Capital-structure state	Amount	Status	Cash to company	Gate or interpretation
Filed common shares	15,765,372	Actual common denominator as of July 29	None	Use as the current denominator; do not add the PIPE again without a newer share-count filing.
July PIPE common shares	1,175,090	Issued in the July 10 closing and reflected in the later filed baseline	Approximately $6M gross PIPE proceeds included with the package	Actual issuance is distinct from later potential exercise.
July PIPE pre-funded warrants	12,643,680 shares	Potential, immediately exercisable	No additional material exercise cash	Potential shares are not current float.
Series A and Series B warrants	13,818,770 shares each	Potential and approval-dependent	Cash exercise could provide proceeds, but timing and exercise are unknown	$0.50 Series A strike and $0.45 Series B strike are anchors, not support levels.
Preferred exchange and conversion	$10.66M Series C value plus 35,648,276 Series A and B preferred shares	Contracted path, subject to stockholder approval	Exchange and conversion are not new cash	Use the S-1 aggregate registration rather than adding an assumed share count.
Resale registration	150,621,827 shares	Registered potential supply, not immediate float	No company proceeds from selling-stockholder resales	The registered amount is about 955% of the filed common count.

The Market Price

The live reference is $0.296 at 14:39:07 UTC, August 3, 2026. Yahoo's chart snapshot showed a $0.252 to $0.300 intraday range and 7,222,918 shares at the latest update.[5] The six-month range in the same snapshot was approximately $0.25 to $6.20, and the computed 14-day RSI was 35.8. That history says the stock has already experienced severe de-rating. It does not prove that the next move must be lower.

The filing-based equity value is approximately $4.67M, calculated as 15,765,372 shares multiplied by $0.296. A separate Yahoo Finance snapshot at $0.2994 displayed a market-cap field of approximately $1.04M.[6] The two values do not reconcile. This article uses the filed share count and treats the vendor field as a data-quality warning, not as a valuation anchor.

The Positioning

Supported fact: The primary filings document actual July PIPE issuance, immediately exercisable pre-funded warrants, approval-dependent warrants, a preferred exchange and conversion path, and a registered resale aggregate. The latest intraday volume is also observable.[1][2][5]

Unknown: I do not have sufficient reliable data to quantify live short interest, borrow availability, borrow cost, utilization, recall risk, options open interest, dealer positioning, fund flows, executable spread, order-book depth, or exit liquidity.

The potential-supply evidence is strong, but the tradeability evidence is incomplete. Positioning is capped at 3/5. No claim is made that today's volume represents short selling or that registered holders are already selling.

The Catalyst

The catalyst path is a sequence, not a single headline:

Registration effectiveness: The July 31 S-1 was filed, but its effectiveness and any resale under it were not independently verified in this run.
Stockholder approval: Approval would activate the Series A and Series B warrants and the preferred exchange and conversion path. The lower quorum may reduce a procedural obstacle, but does not establish the vote outcome.
First hard supply evidence: The cheapest disconfirming test for the short is an 8-K, resale filing, or share-count disclosure showing actual issuance, exercise, proceeds, and post-transaction common shares.
Cash adjudication: The next 10-Q should reconcile cash after the July PIPE, operating cash flow, net loss, short-term liabilities, current share count, and any warrant exercise.
Counter-catalyst: A credible customer contract, non-dilutive financing, or commercial acceleration can turn potential supply into a balance-sheet bridge and force a squeeze before resales occur.

The Gap

Fact: CYAB reported $1.415M of revenue, a $10.770M net loss, $2.598M of operating cash burn, and $3.122M of cash at March 31, 2026. Its filing stated that it needed additional capital and carried substantial doubt about its ability to continue as a going concern.[4]

Inference: The financing and resale stack creates a plausible near-term pressure path that is more specific than a generic “AI microcap” short.

Counter-inference: The July PIPE raised approximately $6M gross, the company has a commercial product, and exercise of certain warrants could provide additional cash. If stockholder approval simplifies the preferred structure and the operating story improves, the same securities that create dilution risk can create a financing bridge and a violent squeeze.

Canonical Rubric

Dimension	Desk reading
Price	$0.296 reference price is below the $0.435 PIPE price and below the $0.45 to $0.50 warrant levels, but the stock has already fallen sharply.
Positioning	150.6M registered potential shares versus 15.8M filed common shares; borrow, short interest, options, dealer flow, and fund flow are unverified.
Catalyst	S-1 effectiveness, stockholder approval, first exercise or resale, and the next cash and share-count filing.
Reality	Revenue exists, but Q1 loss, cash burn, going-concern language, and the need for additional financing remain hard constraints.
Expression	Conditional, staged CYAB common-stock short only after failed continuation and verified locate, borrow, spread, depth, and exit liquidity. No unsupported options expression.

Price Target and Probability Map

Scenario	Probability	Target / level	Reference-relative short payoff	Time horizon	Conditions required	Evidence quality
Top case for short, squeeze risk	30%	$0.50	-68.9%	1-6 weeks	Approval, credible funding, strong customer evidence, or holder delay overwhelms the supply path.	Medium
Base case for short	45%	$0.18	+39.2%	1-6 weeks	Registration or approval advances into observable supply while cash and burn remain weak.	Medium
Bottom case for short	25%	$0.05	+83.1%	2-8 weeks	Multiple supply gates open, resales become visible, and no non-dilutive funding offsets the runway problem.	Low to medium

Probability-weighted reference-relative short return: approximately +17.7% before borrow, locate fees, financing, slippage, gap risk, and taxes, using 30% x -68.9% + 45% x 39.2% + 25% x 83.1%. This is a scenario map, not an executable trade EV. There is no responsible entry price because the required execution data is missing.

Invalidation / review level: $0.50 is a risk-control review level, not a guaranteed stop. A sustained move above it accompanied by no actual resale, credible non-dilutive funding, commercial improvement, or a failed approval path would require abandoning the supply-led short thesis. A price print alone is not sufficient proof either way.

What Could Go Wrong

The strongest counterargument is that the supply is contractual and conditional, while the business can still improve. The stock already trades below the PIPE price, so some dilution risk is probably reflected. Pre-funded warrants may not be exercised immediately. The Series A and B warrants, preferred exchange, and preferred conversion need stockholder approval. Holders may wait rather than sell. A customer or financing headline can dominate the capital-structure arithmetic.

Other failure modes are mechanical. A halt, a wide spread, shallow depth, hard-to-borrow status, recall, or an intraday squeeze can make a correct thesis untradeable. The provider market-cap conflict shows that even basic denominator fields require reconciliation. The Q1 cash and burn data are not current enough to prove the post-PIPE runway.

What Would Prove This Wrong

The thesis should be downgraded or closed if the next filings show materially better cash coverage without new common dilution, if stockholder approval fails and the preferred and warrant stack remains locked, if the S-1 expires or remains unused while the company produces credible operating improvement, or if actual resale activity is immaterial and the stock sustains strength above the $0.50 review level. A registration statement alone cannot prove the short right or wrong.

Best Trade Strategy

Direction: Conditional short, watch-only until a hard supply event and failed continuation are visible.

Preferred instrument: CYAB common stock only, staged after a verified locate and acceptable borrow. entry.price: null.

Common-stock stance: No price-specific entry at the current intraday snapshot. Do not short the intraday low. Require a failed reclaim or failed continuation after actual issuance, exercise, resale, or approval evidence.

Options stance: No options expression. A liquid live chain, spreads, implied volatility, open interest, and dealer positioning were not verified.

TP: $0.18 first target, $0.05 tail target.

SL / invalidation: Review at $0.50 and exit or abandon if the price and fundamental invalidation conditions above are met. Gap risk means a displayed stop is not assumed to be executable.

Timeline: One to six weeks, with a longer tail if the approval and resale sequence is delayed.

Execution risks: Locate failure, borrow recall, borrow cost, low depth, halted trading, intraday gaps, approval squeeze, non-dilutive funding, customer-news volatility, and a stale or conflicting market-cap field.

Do-not-trade conditions: No locate or acceptable borrow; no fresh quote, spread, depth, venue, or exit-liquidity check; no actual supply event; price is at an intraday low; the expected payoff is consumed by borrow and slippage; or a liquid options chain is not verified.

Monitoring checklist: S-1 effectiveness, first resale, pre-funded exercise, stockholder meeting notice and vote, July PIPE and preferred transaction share counts, next 10-Q cash and operating burn, revenue and customer evidence, quote range and volume, borrow and recall terms, short interest, options, spread, depth, and exit liquidity.

Bottom Line

CYAB is not a clean “150.6M shares are coming” short. It is a conditional mismatch between a 15.8M filed common denominator and a 150.6M registered claim stack whose approval and resale gates are becoming easier to observe. The price is already below the PIPE anchor and the operating business can still create a squeeze. That leaves a useful research setup, but not a trade: wait for actual supply, failed continuation, and verified borrow and liquidity. Until then, the signal is watch-only and execution is fail-closed.

Research Quality Scorecard

Criterion	Score	Evidence note
Market disagreement	5	A small filed common denominator sits beneath a much larger, newly registered and partly approval-dependent claim stack.
Evidence base	5	July 9 and July 31 SEC filings, March 31 10-Q, and a timestamped market-data snapshot support the core bridge.
Positioning and flows	3	Potential supply and unusual volume are visible, but borrow, short interest, options, dealer, fund-flow, spread, and depth data are missing.
Catalyst path	5	S-1 effectiveness, stockholder approval, first exercise or resale, and the next cash and share-count filing are observable tests.
Payoff architecture	4	Top, base, and bottom cases sum to 100%, but the price map is conditional and not executable.
Invalidation discipline	5	Price, filing, operating, approval, and execution invalidators are explicit.
Differentiated insight	5	The key distinction is registered claim stack versus actual float, with the quorum amendment as a procedural catalyst.
Client value	4	Useful as a dilution and approval monitoring framework even if no short is taken.
Total	36 / 40	Publishable Short Note; missing market-structure data prevents an active trade signal.

Sources

AI Illustration Prompt

Realistic, high-end editorial cover image for The Mispricing Desk: a dark graphite trading ledger labeled “CYAB” with a small solid block of 15.8 million common-share tiles beneath a vast translucent field of 150.6 million claim tiles, some marked “pre-funded warrant,” “Series A,” “Series B,” and “preferred conversion,” separated by a glass approval gate marked “33 1/3% quorum.” Behind the ledger, a restrained AI reputation-monitoring interface glows in muted teal, while a thin red resale-registration line approaches but does not touch the common-share block. Sophisticated Bloomberg Markets or Barron's composition, off-white paper, graphite, muted amber, and teal palette, precise financial-engineering symbolism, cinematic studio lighting, no generic stock-photo language, no hype, and a subtle but clear watermark reading “The Mispricing Desk”.